Mersana Therapeutics to Provide Update on the Progress of its UpRi Clinical Development Strategy and Report Interim Data from the Ovarian Cancer Expansion Cohort of the UpRi Phase I Study
Mersana Therapeutics (NASDAQ:MRSN) has announced a live conference call and webcast on September 10, 2021, at 8:00 a.m. ET to discuss the development strategy of its ADC candidate, upifitamab rilsodotin (UpRi), and share updated interim data from the ovarian cancer expansion cohort of the Phase 1 study. The expansion cohort has completed enrollment with 97 patients evaluable for safety, of which 75 are RECIST-evaluable. Key executives, including lead investigator Debra L. Richardson, MD, will participate in the call.
- Completion of enrollment in the ovarian cancer expansion cohort with 97 patients evaluable for safety.
- 75 out of 97 patients are RECIST-evaluable at this interim analysis.
- None.
Conference call and webcast on Friday, September 10, 2021, at 8:00 a.m. ET featuring lead investigator Debra L. Richardson, MD
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live conference call and webcast on Friday, September 10, 2021 at 8:00 a.m. ET to discuss the progress of its clinical development strategy for upifitamab rilsodotin (UpRi) and report updated interim data from the ovarian cancer expansion cohort of the UpRi Phase 1 study. Enrollment in the expansion cohort is complete with 97 patients evaluable for safety and tolerability, of which 75 are RECIST-evaluable at this interim analysis.
Members of the Mersana executive team will be joined by lead investigator, Debra L. Richardson, MD Associate Professor and Section Chief of Gynecologic Oncology at the Stephenson Cancer Center at the University of Oklahoma Health Sciences Center and the Sarah Cannon Research Institute.
Conference Call Details
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1441618. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. UpRi is also being studied in the expansion portion of a Phase 1 proof-of-concept clinical study. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the Company’s clinical strategy for its product candidates, progression and timing of its clinical study and release of data from its clinical study, the ability of the single-arm UPLIFT cohort to enable registration, and expectations regarding future clinical trial results. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “opportunity,” “plans,” “poised for,” “possible,” “potential,” “predicts,” “projects,” “promises to be,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations and whether these forward-looking statements prove to be correct include, among other things, that preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later preclinical or clinical studies, that results of the Company’s ongoing or future clinical studies may be inconclusive with respect to the efficacy of the Company’s product candidates, that the Company may not meet clinical endpoints with statistical significance or there may be safety concerns or adverse events associated with product candidates, that the identification, development and testing of the Company’s product candidates and new platforms will take longer and/or cost more than planned, and that the Company’s clinical studies may not be initiated or completed on schedule, if at all, as well as those listed in the Company’s Quarterly Report on Form 10-Q filed on August 6, 2021, with the Securities and Exchange Commission (“SEC”), and subsequent SEC filings. In addition, while we expect that the COVID-19 pandemic may adversely affect the Company’s preclinical and clinical development efforts, business operations and financial results, the extent of the impact on the Company’s operations and the value of and market for the Company’s common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the spread of variants of COVID-19, including the Delta variant, travel restrictions, quarantines, physical distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Contact:
Investor & Media Contact
Sarah Carmody, 617-844-8577
scarmody@mersana.com
FAQ
What is the purpose of the upcoming Mersana Therapeutics conference call on September 10, 2021?
How many patients are involved in the UpRi Phase 1 study expansion cohort?
What are the RECIST-evaluable results for the UpRi Phase 1 study?
Who will be speaking during the Mersana Therapeutics conference call?
